-
-
-
The Expanding Benefits of GLP-1 Medicines
Diabetes
Discover the expanding benefits of GLP-1 drugs beyond diabetes and obesity, including improvements in heart, kidney, liver, joint, brain health, and more, as summarized by GLP-1 pioneer Daniel J. Drucker.
-
EU Confirms Vision Risk Tied to Semaglutide
EMA
EU regulators have confirmed a rare risk of vision loss linked to Novo Nordisk’s semaglutide, used in Wegovy and Ozempic. Drug labels will be updated to reflect the potential for NAION, a serious but very rare eye condition.
-
-
Top 10 Best-Selling Drugs in Q1 2025
Market Trend
Discover the top 10 best-selling drugs of Q1 2025. GLP-1 drugs dominate, with semaglutide and tirzepatide leading growth. Oncology and autoimmune treatments face challenges amid rising competition and patent expirations.
-
-
-
-
鄂州市|
金坛市|
门源|
鄯善县|
荥经县|
淮滨县|
新民市|
澄城县|
茶陵县|
赤城县|
天柱县|
昌图县|
筠连县|
阿尔山市|
拉孜县|
玉山县|
竹北市|
栖霞市|
互助|
抚远县|
金堂县|
巨鹿县|
诸城市|
南溪县|
镇沅|
宣城市|
五华县|
德钦县|
论坛|
嫩江县|
庆云县|
金堂县|
麟游县|
游戏|
右玉县|
集贤县|
铜陵市|
卫辉市|
安乡县|
龙州县|
北流市|